Linda L. Logan

Linda L. Logan

Auto-generated profile, based on publicly available information

Linda L. Logan

University of Colorado Anschutz Medical Campus 1 Department of Pathology Aurora, Colorado

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
NSNicole S. Spoelstra
Nicole S. Spoelstra
MWMichelle M Williams
Michelle M Williams
LLLinda L. Logan
Linda L. Logan
KOKathleen O'Neill
Kathleen O'Neill
JRJennifer K. Richer
Jennifer K. Richer
When tumor cells colonize distant organs during metastasis, they interact extensively with surrounding cells. These interactions often change the behavior of surrounding cell populations which collectively induce a protumor microenvironment that permits tumor cell outgrowth into overt, clinically detectable metastatic disease. The lung is one of the most common sites of breast cancer metastasis. A chronic wound repair–related phenotype developed within the lung microenvironment during metastatic outgrowth in immunocompetent preclinical mouse models of breast cancer. This phenotype was characterized by an increased number and activation of lung type II alveolar epithelial (AT2) cells surrounding growing metastases. Metastatic outgrowth significantly changed AT2 gene expression, resulting in a modified secretome. AT2-derived secreted factors also promoted triple-negative breast cancer growth. AT2-secreted factors are regulated by the cyclic adenosine monophosphate response element-binding protein (CREB). Targeting CREB signaling with the phosphodiesterase 4 (PDE4) inhibitor roflumilast reduced AT2 breast cancer reciprocal interactions in vitro and metastatic outgrowth in vivo. Finally, AT2 cells adjacent to metastases in lungs from patients with metastatic breast cancer expressed higher PDE4B compared with AT2 cells in normal lungs. Significance: Alveolar epithelial cells are the most common cell type in the lung. Our studies demonstrate the potential for targeting metastasis-associated wound repair and lung epithelial cell activation during metastatic outgrowth with FDA-approved PDE4 inhibitors. This strategy may be an effective way to treat and manage progression of established metastatic breast cancer within the lung.


17 June 2026
Verified
Other
Open access
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
NSNicole S. Spoelstra
Nicole S. Spoelstra
MWMichelle M Williams
Michelle M Williams
LLLinda L. Logan
Linda L. Logan
KOKathleen O'Neill
Kathleen O'Neill
JRJennifer K. Richer
Jennifer K. Richer
AT2 pathways associated with BC interaction.

17 June 2026
Verified
Other
Open access
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
NSNicole S. Spoelstra
Nicole S. Spoelstra
MWMichelle M Williams
Michelle M Williams
LLLinda L. Logan
Linda L. Logan
KOKathleen O'Neill
Kathleen O'Neill
JRJennifer K. Richer
Jennifer K. Richer
Cell activation in metastatic lungs.


17 June 2026
Verified
Other
Open access
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
NSNicole S. Spoelstra
Nicole S. Spoelstra
MWMichelle M Williams
Michelle M Williams
LLLinda L. Logan
Linda L. Logan
KOKathleen O'Neill
Kathleen O'Neill
JRJennifer K. Richer
Jennifer K. Richer
ScRNAseq analysis of metastatic outgrowth in lungs.